Forecast

There is no analyst data available for this company.

News Go to news feed

Diagnostyka records strong growth in H1 2026 and confirms full-year guidance

Diagnostyka reports H1 2026 revenue up 16% to PLN 683 million and recurring EBITDA of PLN 154.4 million (+22.6%). B2B revenue rose sharply and now accounts for more than 64% of group revenue, while test volume increased by only 4.1%. Free cash flow fell 25% due to higher receivables; net debt stands at PLN 1.2 billion. Management confirms the full-year guidance despite cost and SAP-related expenses. The company plans further organic growth, investments in imaging diagnostics and expanded presence in clinical-trial diagnostics. » More on de.investing.com
Diagnostyka increases revenue by 26.7% and earnings per share to 2.31 PLN

Diagnostyka presented figures for the quarter to Sept. 30, 2025: earnings per share rose to 2.31 PLN from 1.47 PLN a year earlier. Revenue grew by 26.65% to 612.3 million PLN, up from 483.5 million PLN in the year-ago period. The numbers were presented at the financial conference on Nov. 20, 2025. » More on finanzen.net